Deals
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
BioStem Technologies’ buyout of BioTissue Holding’s surgical and wound-care business adds cryopreserved and sterile technologies, Cryotek and SteriTek, and a direct sales force focused on acute care settings.
Boston Scientific’s $14.5bn Deal Folds Penumbra Thrombectomy Platforms Into Cardiovascular Franchise
Subject to shareholder approval,Boston Scientific will acquire Penumbra for approximately $11bn in cash on hand and new debt, and issue 41 million shares for the remaining $4bn.
The market is assessing how the blocked JenaValve transaction affects Edwards Lifesciences’ longer-range growth, particularly following targets laid out at the company’s December 2025 investor day.
An interactive look at medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.
Our experts said investor confidence in medtech is recovering as we head into 2026. Expect larger, selective fundraising and heightened M&A activity, focusing on innovative firms in neurology, cardiovascular health, and AI-driven technologies. Companies with solid strategies are favored.
Analysts caution that while board-level changes at STAAR Surgical could ultimately unlock value, the lead time may depress performance, particularly given demand recovery in key markets such as China. At the same time, Alcon’s next move remains an open question.
Withings announced at CES that its health monitoring app will integrate data from Abbott’s OTC CGM Lingo starting in Q1.
Last year was a busy one for the medtech industry, with major advances in technology as well as big changes at regulatory agencies. Get a peek at the stories our readers couldn't miss.
Ireland's medtech ecosystem continues to flourish, with more than 50,000 employees across 700 companies. The sector set a venture capital record in 2024 and is on pace to match or exceed it this year.
Medtech leaders expect faster change in 2026 as AI integration speeds up across all business aspects, according to a Deloitte survey of medtech execs that also predicted M&A activity will remain strong in 2026. While optimism is high, uncertainties remain.
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
An interactive look at medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech funding in 2025 sees a trend of fewer, yet larger deals with total funding of $3.6bn in Q1, $2.6bn in Q2 and $2.9bn in Q3, said LSI’s Nick Talamantes. In 2026, he expects a continued investor focus on more mature firms in areas of oncology, cardiology and neurology.
Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.
With this acquisition, GE HealthCare is trying to accelerate the shift toward integrated solutions including hardware, software, cloud and workflow tools rather than standalone hardware – an area peers will also need to pursue to defend margins. Analysts expect near-term EPS dilution.
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
INBRAIN teamed up with Microsoft to apply agentic AI to analyze real-time brain data and eventually recommend programming like a “mini-neurologist,” said CEO Carolina Aguilar. It also seeks to enable scalable deployment of INBRAIN’s graphene-based technology and potential joined research.
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.